(Q35609686)

9 August 2017

1 reference

title

Trastuzumab-based combination therapy for breast cancer (English)

1 reference

9 August 2017

1 reference

Filippo Montemurro

1

1 reference

ORCID Public Data File 2021

author name string

Giorgio Valabrega

series ordinal

2

1 reference

PubMed ID

14680438

9 August 2017

Massimo Aglietta

series ordinal

3

1 reference

PubMed ID

14680438

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

1 reference

9 August 2017

5

1 reference

9 August 2017

81-96

1 reference

9 August 2017

1

1 reference

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Role of HER2 in wound-induced breast carcinoma proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Receptor blockade with monoclonal antibodies as anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

A review of vinorelbine in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Gemcitabine and targeted therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Capecitabine: fulfilling the promise of oral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.81

21 January 2018

Identifiers

DOI

10.1517/14656566.5.1.81

1 reference

9 August 2017

1 reference

PubMed ID

14680438